Galectin Therapeutics Inc [GALT] stock is trading at $6.0, up 3.27%. An important factor to consider is whether the stock is rising or falling in short-term value. The GALT shares have gain 17.65% over the last week, with a monthly amount glided 38.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright reaffirmed its Buy rating on August 13, 2020, and elevated its price target to $12. On February 13, 2019, B. Riley FBR initiated with a Buy rating and assigned a price target of $11 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $10 on December 07, 2017. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $6 on November 28, 2017. In a note dated March 30, 2017, H.C. Wainwright upgraded a Buy rating on this stock but restated the target price of $3.50.
Galectin Therapeutics Inc [GALT] stock has fluctuated between $0.73 and $6.55 over the past year. Galectin Therapeutics Inc [NASDAQ: GALT] shares were valued at $6.0 at the most recent close of the market.
Analyzing the GALT fundamentals
Gross Profit Margin for this corporation currently stands at -0.08% with Operating Profit Margin at -944.89%, Pretax Profit Margin comes in at -1120.53%, and Net Profit Margin reading is -1120.53%. To continue investigating profitability, this company’s Return on Assets is posted at -2.59, Equity is 0.38 and Total Capital is -7.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.73 points at the first support level, and at 5.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.15, and for the 2nd resistance point, it is at 6.29.
Ratios To Look Out For
For context, Galectin Therapeutics Inc’s Current Ratio is 1.43. On the other hand, the Quick Ratio is 1.43, and the Cash Ratio is 1.28.
Transactions by insiders
Recent insider trading involved 10X Fund, L.P., 10% Owner, that happened on Oct 22 ’25 when 50000.0 shares were sold. Chief Financial Officer, CALLICUTT JACK W completed a deal on Sep 12 ’25 to sell 8706.0 shares. Meanwhile, President and CEO LEWIS JOEL sold 14000.0 shares on Sep 12 ’25.
